Atrial fibrillation

Heart Disease

Volumn 4, Issue 2, 2002, Pages 91-101

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; ENCAINIDE; ESMOLOL; FLECAINIDE; IMIPRAMINE; LIDOCAINE; MEXILETINE; MORACIZINE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TOCAINIDE; VERAPAMIL; WARFARIN;

ACUTE HEART INFARCTION; ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CAUSE OF DEATH; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HUMAN; HYPOTENSION; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; META ANALYSIS; MORTALITY; PATIENT SELECTION; PREVALENCE; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; SYNCOPE; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 0036117982     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200203000-00006     Document Type: Review

References (123)

1. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
2. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients
3. Prevalence and incidence of cardiovascular disease in 1,160 older men and 2,464 older women in a long-term health care facility
4. Prevalence of atrial fibrillation in elderly subjects (the cardiovascular health study)
5. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke
6. Incidence of and risk factors for atrial fibrillation in older adults
7. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm
8. Pathophysiology and prevention of atrial fibrillation
9. Echocardiographic findings associated with atrial fibrillation in 1,699 patients aged > 60 years
10. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons
11. Epidemiologic features of chronic atrial fibrillation: The Framingham study
12. Impact of atrial fibrillation on the risk of death: The Framingham heart study
13. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease
14. Acute myocardial infarction complicated by atrial fibrillation in the elderly: Prevalence and outcomes
15. New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience
16. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial
17. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2,384 older persons
18. Association of extracranial carotid arterial disease and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 1,846 older persons
19. Paroxysmal atrial fibrillation: High frequency of embolic brain infarction in elderly autopsy patients
20. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
21. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLID trials
22. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm
23. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
24. Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control
25. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A recta-analysis
26. Tachycardia related cardiomyopathy: A common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation
27. Pacemaker therapy in patients with atrial fibrillation
28. Treatment of arrhythmias with pindolol
29. Acebutolol in supraventricular arrhythmias
30. Use of beta-adrenergic blockers in antiarrhythmic therapy
31. Efficacy and safety of esmolol vs propranotol in the treatment of supraventricular tachyarrhythmias: A multicenter doubleblind clinical trial
32. Verapamil in atrial fibrillation and atrial flutter
33. Efficacy and safety of intravenous diltiazern for treatment of atrial fibrillation and atrial flutter
34. Digoxin for converting recent onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial
35. Digoxin for atrial fibrillation: A drug whose time has gone?
36. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: Which is the preferred treatment?
37. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent
38. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation
39. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation
40. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens
41. Amiodarone for refractory atrial fibrillation
42. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
43. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin
44. Double-blind placebo controlled trial ofdigoxin in symptomatic paroxysmal atrial fibrillation
45. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation
46. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness
47. Long-term follow-up after radio-frequency modification of the atrioventricular node in patients with atrial fibrillation
48. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractoury atrial fibrillation
49. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
50. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized, controlled study
51. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation
52. Successful surgical treatment of atrial fibrillation: Review and clinical update
53. Sinus node-atrioventricular node-atrioventricular node isolation: Long-term results with the "Corridor" operation for atrial fibrillation
54. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci
55. Catheter maze-ablation for preventing atrial fibrillation: Where do we stand?
56. Atrioverter: An implantable device for the treatment of atrial fibrillation
57. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities
58. Prospective randomised trial of atrial versus ventricular pacing in sick sinus syndrome
59. Prevalence of arrhythmias detected by 24-hour ambulatory electrocardiography and value of antiarrhythmic therapy in elderly patients with unexplained syncope
60. Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: Experience with 6 cases
61. Atrial pacing periablition for prevention of paroxysmal atrial fibrillation
62. Randomized prospective pilot study of long-term dual-site atrial pacing for prevention of atrial fibrillation
63. Dual-site atrial pacing for atrial fibrillation in patients without bradycardia
64. Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting
65. Treatment of underlying atrial fibrillation: Paced rhythm obscures recognition
66. Clinical perspectives in management of Wolff-Parkinson-White syndrome. Part 2: Diagnostic evaluation and treatment strategies
67. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current
68. Electrical conversion of atrial fibrillation: Immediate and long-term results and selection of patients
69. Transthoracic cardioversion of atrial fibrillation. Comparison of rectilinear biphasic versus damped sine wave monophasic shocks
70. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs
71. Proarrhythmia in patients treated for atrial fibrillation or flutter
72. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
73. Cardiac arrhythmia suppression trial. Preliminary report: Effect of encainide and flecainide on mortally in a randomized trial of arrhythmia suppression after myocardial infarction
74. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter
75. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
76. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study
77. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
78. Transesophageal echocardiographically facilitated early cardioversion front atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
79. Antithrombotic therapy in atrial fibrillation
80. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for "atrial stunning" as a mechanism of thromboembotic complications
81. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study
82. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
83. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography
84. Strategies for cardioversion of atrial fibrillationtime for a change?
85. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: Should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis
86. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A recta-analysis of randomized control trials
87. Effect of quinidine or procainimide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias
88. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
89. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
90. Antiodarone to prevent recurrence of atrial fibrillation
91. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized, double-blind, placebo controlled study
92. Antiarrhythmic effects of azimilde in atrial fibrillation: Efficacy and dose-response
93. Antiarrhythmic drug therapy and cardiac imortality in atrial fibrillation
94. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials
95. Effect of propranolol versus no antiarrhythmic drug on sudden death, total cardiac death, and total death in patients ≥ 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≤ 40%
96. Management of atrial fibrillation after coronary artery bypass graft
97. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): A randomised trial
98. Atrial fibrillation follow-up investigation of rhythm management: The AFFIRM study design
99. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
100. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
101. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients
102. Risk factors for new thromboembolic stroke in persons ≥ 62 years old with chronic atrial fibrillation
103. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation
104. Predictors of thromboembolism in atrial fibrillation: II. Echocardiocardiographic features of patients at risk
105. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
106. Association of extracranial carotid arterial disease and chronic atrial fibrillation with die incidence of new thromboembolic stroke in 1,846 older persons
107. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk
108. Risk factors for thromboembolic complications in chronic atrial fibrillation
109. Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2,148 persons, mean age 81 years
110. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
111. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation
112. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study
113. Stroke Prevention in Atrial Fibrillation Study: Final results
114. Canadian atrial fibrillation anticoagulation (CAFA) study
115. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
116. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study
117. Incidence of new thromboembolic stroke in persons ≥ 62 years old with chronic atrial fibrillation treated with warfarin versus aspirin
118. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction
119. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
120. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke Prevention in Atrial Fibrillation III Study
121. Cardiovascular drug therapy in the elderly
122. Antithrombotic therapy in atrial fibrillation
123. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation